Dr. Subha Madhavan is a leader in bioinformatics, data science, clinical informatics and health IT who has initiated, designed, and executed large national and international biomedical research programs. As founder and managing partner of Technology for Science, LLC (TFS), she provides consulting services to many organizations in the fields of bioinformatics strategy and technology development. In this role, she advises the CEO and CMO of Perthera Inc., a personalized medicine company providing clinical genomic services to cancer patients and their oncologists. She developed the go-to-market strategy for their primary product, an oncology expert system that uses multi-omic molecular diagnostics and cutting edge bioinformatics to rank and inform therapeutic options for patients with advanced, refractory cancers. As the founding director of the Innovation Center for Biomedical Informatics at Georgetown University, she recruits and mentors bioinformatics and computer scientists and manages a total operating budget of over $30M. She has initiated and successfully directed productive, collaborative NIH Bioinformatics programs, hospital networks, other NIH programs, FDA, academic medical centers, and industry. More recently, she has partnered with the FDA as Principal Investigator of Bioinformatics for the Center for Excellence in Regulatory Science program. Under her able direction, CERSI developed regulatory grade evidence databases for pharmacogenomics and vaccine safety, as well as novel biomarker based basket and umbrella trial designs that utilize real world evidence from EHRs. She initiated the Cloud First program at Georgetown University through a strong partnership with Amazon Web Services; this initiative will develop and deploy next generation cloud computing platforms for high dimensional research datasets, including next generation sequencing and de-identified patient datasets. Through TFS, she has provided Bioinformatics consulting services to MedStar Health, National Children's medical center, UCSF, University of Michigan Cancer Center and others. Her scientific research encompasses critical areas in Cancer Precision Medicine and Big Data including next generation molecular algorithms for cancer biomarker discovery, systems biology, computational modeling, biocuration through automated natural language processing techniques, and policy barriers to implementation of personalized medicine. She has contributed to novel information sciences findings in journals such as Nature, Bioinformatics, Molecular and Cell Biology (MCB), AJPM, Frontiers in Oncology, Cancer Informatics, and Molecular Cancer Research (MCR). She Chaired AMIA's signature annual event in Translational Bioinformatics in Spring, 2016.
[Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.]
Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.